Novartis' Gilenya: Down But Not Out With NICE
This article was originally published in The Pink Sheet Daily
Executive SummaryNovartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.
You may also be interested in...
The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.
NICE says that additional information provided by Novartis does not satisify its requirement for proof of cost-effectiveness of Gilenya.